Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:INSM 13 August 2025 - 2 January 2026

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia shares fell about 8% Friday, closing at $31.70 after swinging between $30.76 and $34.97 on heavy volume. Options trading showed a surge in put buying, with 15,696 contracts traded, 56% above normal. The drop outpaced biotech peers as investors watched for updates on the company’s patent dispute over Yutrepia and its next earnings report, expected March 18.
2 January 2026
···
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed shares closed Monday at $175.76, up 0.53%, then traded between $175.76 and $178.05 after hours. The stock joined the Nasdaq-100 effective Dec. 22, prompting index-related activity. No new company announcements appeared after the bell. Investors continued to weigh last week’s brensocatib CRSsNP trial failure.
23 December 2025
··
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed joined the Nasdaq-100 Index on December 22, 2025, boosting its stock visibility. Shares traded at $177.86, up 1.7%, after recent swings triggered by a failed Phase 2b trial for brensocatib in chronic rhinosinusitis, which led the company to end that program. Insmed also acquired INS1148, a Phase 2–ready monoclonal antibody, for $40 million upfront.
22 December 2025
·
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed will join the Nasdaq-100 before markets open Monday, December 22, 2025. Shares fell 11% last week after the company halted development of brensocatib in chronic rhinosinusitis without nasal polyps following a failed Phase 2b trial. The stock last traded near $174.84. Holiday trading may affect liquidity and volatility.
21 December 2025
·
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed shares closed Friday, Dec. 19, 2025, at $174.84, up nearly 5%, after a volatile week triggered by a failed Phase 2b trial for brensocatib in CRSsNP. The company said it would discontinue that program. Shares held steady in after-hours trading. Insmed also announced the acquisition of INS1148, a Phase 2–ready monoclonal antibody.
20 December 2025
·
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed shares rose 5% to $174.90 Friday after a steep Thursday drop, following news that its Phase 2b BiRCh trial in CRSsNP missed endpoints and the program was discontinued. Trading volume spiked Thursday as shares fell 16%. The rebound came as analysts reiterated Buy ratings, citing Insmed’s bronchiectasis franchise and respiratory pipeline. The stock remains below its 52-week high of $212.75.
19 December 2025
·
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed shares fell 16% Thursday after the company said its Phase 2b trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet endpoints, prompting it to end development for that indication. The drug’s performance matched or trailed placebo on symptom scores. Insmed reported no new safety issues. The stock traded near $166.75 after hitting a low of $158.06.
18 December 2025
···
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···
Tech World Rocked by 8 Non‑AI Surprises This Week

Tech World Rocked by 8 Non‑AI Surprises This Week

Apple is developing a home companion robot with a 7-inch movable display and advanced Siri, targeting a 2027 launch. The FDA approved Insmed's Brinsupri as the first treatment for non-cystic fibrosis bronchiectasis, priced at $88,000 per year. ULA's Vulcan rocket completed its first operational flight, carrying Space Force payloads from Cape Canaveral. Amazon expanded Prime same-day grocery delivery to over 1,000 U.S. cities.
14 August 2025
···········
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···

Stock Market Today

  • Potential Buyers Eye Gemini's European and UK Crypto Operations Amid Workforce Cuts
    April 9, 2026, 3:16 PM EDT. Gemini, the crypto exchange backed by the Winklevoss twins, faces potential partial acquisition as buyers assess its shuttered European and UK operations. The New York-based firm recently cut 25% of its global workforce and closed non-U.S. and non-Singapore businesses. Interested parties aim to secure regulatory licenses in Europe and the UK, regions where approvals can take years. Under the EU's Markets in Crypto-Assets (MiCA) framework and the UK's Financial Conduct Authority rules, these licenses require regulatory approval during ownership changes. Gemini, Nasdaq-listed since September 2025, offers a full-service crypto platform beyond trading, including custody and payments. Its share price has fallen from an IPO high of above $37 to around $4, reflecting market volatility.

Latest article

Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

9 April 2026
Bitcoin traded near $72,000 Thursday, up 0.3%, after earlier slipping on renewed Middle East tensions. U.S. spot bitcoin ETFs saw $471.4 million in inflows April 6 but $93.9 million in outflows April 8, as Morgan Stanley’s new MSBT fund debuted with $30.6 million. Ether fell 0.9% to $2,210.56. Bitcoin remains 43% below its October 2025 record high.
Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

9 April 2026
Spot silver jumped 2.9% to $76.24 an ounce Thursday, extending gains after a U.S.-Iran ceasefire and a weaker dollar. Gold rose 1.63% to $4,793.07. Analysts warned the truce remains fragile, with markets watching for March U.S. inflation data due Friday. Oil fell below $100 but tensions persisted in the Middle East.
Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

9 April 2026
Spot gold rose 1.6% to $4,789.67 an ounce by 1:30 p.m. ET Thursday as the U.S. dollar weakened and Treasury yields slipped. U.S. gold futures settled 0.9% higher at $4,818.00. Traders watched a fragile ceasefire between Washington and Tehran and awaited Friday’s U.S. inflation data. March saw gold’s steepest monthly drop since 2008, according to China’s central bank.
Dow Jones Today: Industrial Average Climbs as Oil Retreats, but Inflation Risk Keeps Wall Street Wary

Dow Jones Today: Industrial Average Climbs as Oil Retreats, but Inflation Risk Keeps Wall Street Wary

9 April 2026
The Dow Jones rose 247.66 points to 48,155.97 by midday Thursday, following a surge linked to signs of Middle East de-escalation and Israeli plans for peace talks with Lebanon. Oil prices fell over $4 a barrel after Netanyahu’s remarks, but remain 40% above pre-conflict levels. Amazon climbed 4.3% on strong AI revenue. Traders now see only a 30% chance of a Fed rate cut by year-end, down from 56%.
US Stock Market Today: Wall Street Rises Again, but Oil and Fed Fears Keep the Rally on Edge

US Stock Market Today: Wall Street Rises Again, but Oil and Fed Fears Keep the Rally on Edge

9 April 2026
The Dow rose 337 points, or 0.7%, by 1 p.m. Thursday as oil prices retreated after Israel announced direct talks with Lebanon and hopes for a U.S.-Iran ceasefire steadied markets. Amazon shares climbed on news its AWS AI services topped $15 billion in annualized revenue. The Fed signaled possible rate hikes if inflation persists. Oil shipments through the Strait of Hormuz remained sharply reduced.
Go toTop